FORT WASHINGTON, Pa., May 6, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, announced that it will be presenting new data on several of its product candidates for the treatment of autoimmune diseases, atopic dermatitis and acute coronary syndrome at upcoming scientific meetings.
IMMUNOLOGY 2015: The American Association of Immunologists Annual Meeting
New Orleans, LA, May 8-12, 2015
Vitae will present a poster titled, “The potent, selective ROR?t blocker, VTP-43742, suppresses Th17 production in vivo and provides greater benefit than IL-17 blockade in the EAE model of autoimmunity.” VTP-43742 is Vitae’s novel, potential first-in-class ROR?t inhibitor being developed for autoimmune disorders.
Date: Saturday, May 9, 2015
Time: 2:30-3:45 p.m. CDT
Location: Ernest N. Morial Convention Center, Exhibit / Poster Hall
In addition, Gerard McGeehan, Ph.D., Vice President, Biology at Vitae will deliver an oral podium presentation titled “VTP-43742 is a potent and selective ROR?t blocker that demonstrates oral efficacy in a mouse model of autoimmunity through suppression of IL-17A production.”
Date: Sunday, May 10
Time: 4:15-4:30 p.m. CDT
Location: Ernest N. Morial Convention Center, Room R08
The same data will be presented in a poster session.
Date: Monday, May 11, 2015
Time: 2:30-3:45 p.m. CDT
Location: Ernest N. Morial Convention Center, Exhibit / Poster Hall
For more information on IMMUNOLOGY 2015, visit http://immunology2015.org/.
2015 Society for Investigative Dermatology Annual Meeting
Atlanta, GA, May 6-9, 2015
Vitae will present a poster titled “The LXR ligand VTP-38543 represents a new class of therapeutic agents for the treatment of atopic dermatitis.” VTP-38543 is Vitae’s novel, potential first-in-class LXR ligand being developed for atopic dermatitis.
Date: Saturday, May 9, 2015
Time: 10 a.m.-12 p.m. EDT
Location: Hilton Atlanta, Galleria Exhibit Hall
For more information on the Society for Investigative Dermatology Annual Meeting, visit http://www.sidnet.org/2015annualmeeting.
Arteriosclerosis, Thrombosis, and Vascular Biology Peripheral Vascular Disease 2015 Scientific Sessions
San Francisco, CA, May 7-9, 2015
Vitae will present a poster titled “The LXRß Selective Agonist, VTP-38443, Significantly Decreases Plaque Cholesterol Ester Content and Inflammation in a Murine Model of Accelerated Atherosclerosis.” VTP-38443 is Vitae’s novel, potential first-in-class LXRß partial agonist being developed for acute coronary syndrome.
Date: Friday, May 8, 2015
Time: 5:30-7:30 p.m. PDT
Location: Hilton San Francisco Union Square, Grand Ballroom A
For more information on the Arteriosclerosis, Thrombosis, and Vascular Biology Peripheral Vascular Disease 2015 Scientific Sessions, visit http://my.americanheart.org/professional/Sessions/ATVBPVD/ATVBPVD-Scientific-Sessions_UCM_316902_SubHomePage.jsp.
About Vitae
Vitae Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing novel, small molecule drugs for diseases in which there are significant unmet medical needs, including disclosed programs in diabetes, Alzheimer’s disease, autoimmune disorders, atopic dermatitis and acute coronary syndrome. This robust and growing portfolio of novel product candidates is generated by Contour®, Vitae’s proprietary structure-based drug discovery platform.
For additional information, please visit the company’s website at www.vitaepharma.com.
CONTACT: INVESTORS: Vitae Pharmaceuticals, Inc. Richard S. Morris, CPA Chief Financial Officer (215) 461-2000 rmorris@vitaerx.com Westwicke Partners John Woolford (443) 213-0506 john.woolford@westwicke.com MEDIA: 6 Degrees PR Tony Plohoros (908) 940-0135 tplohoros@6degreespr.com
Help employers find you! Check out all the jobs and post your resume.
